Diabetic ulcers present a formidable obstacle in diabetes management, typically leading to high mortality and amputation?rates. To?overcome traditional monotherapy drawbacks, We developed a novel microneedle strategy for combined antimicrobial action: ingeniously integrating quercetin with Platelet-derived Growth Factor-BB(PDGF-BB) and Sucrose Octasulfate(SOS) into the microneedle system(QPS MN). This method allows to penetrate through biofilms, administering quercetin nanocrystals and PDGF-BB deep into the tissue to combat microbial infection, mitigate inflammation, and promote angiogenesis. The accompanying backing material contains SOS, which absorbs wound exudate and forms a dressing that provides a moist environment for wound healing In an in vitro wound-scratch assay demonstrated that ?Human Umbilical Vein Endothelial Cells(HUVEC) with QPS MN for 48?h (90.3?±?2.51?%) significantly enhanced cell migration compared to the control group (20.2?±?1.41?%). Moreover, treatment of streptozotocin-induced diabetic wounds in rats with QPS MN for 14?days resulted in a wound healing rate of 96.56?±?3.44?%, far surpassing the healing rate of only 40.34?±?7.26?% observed in the untreated control group. Furthermore, the QPS MN treated wounds exhibited a notable increase in skin appendages and neovascularisation, indicating promising potential for achieving complete wound healing. These results suggest that QPS MN may offer substantial therapeutic benefits for addressing diabetic wounds.